**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 15695**

**Columns: SYSTEMATIC REVIEWS**

**Antioxidant drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: What does evidence suggest?**

Fuentes-Orozco C *et al.* Antioxidants to prevent post-ERCP pancreatitis

Clotilde Fuentes-Orozco, Carlos Dávalos-Cobián, Jesús García-Correa, Gabriela Ambriz-González, Michel Dassaejv Macías-Amezcua, Jesús García-Rentería, Jorge Rendón-Félix, Mariana Chávez-Tostado, Lizbeth Araceli Cuesta-Márquez, Andrea Socorro Alvarez-Villaseñor, Ana Olivia Cortés-Flores, Alejandro González-Ojeda

**Clotilde Fuentes-Orozco, Jesús García-Correa, Michel Dassaejv Macías-Amezcua, Jesús García-Rentería, Mariana Chávez-Tostado, Lizbeth Araceli Cuesta-Márquez, Ana Olivia Cortés-Flores, Alejandro González-Ojeda,** Research Unit in Clinical Epidemiology, Specialties Hospital of the Western Medical Center, Medical Unit of High Specialty, Mexican Institute of Social Security, Guadalajara, Jalisco 44340, México

**Carlos Dávalos-Cobián, Jesús García-Correa,** Department Gastrointestinal Endoscopy, Specialties Hospital of the Western Medical Center, Medical Unit of High Specialty, Mexican Institute of Social Security, Guadalajara, Jalisco 44340, México

**Gabriela Ambriz-González,** Department of Pediatric Surgery. Children’s Hospital. Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco 44340, México

**Andrea Socorro Alvarez-Villaseñor,** Health Research Coordination. Mexican Institute of Social Security, Baja Californa Sur 23000, Mexico

**Author contributions:** Fuentes-Orozco C, García-Rentería J, Rendón-Félix J, Chávez-Tostado M, Cuesta-Márquez LA, Macías-Amezcua MD, Cortés-Flores AO, Ambriz-González G, Alvarez Villaseñor AS and González-Ojeda A participated in the protocol design, reviewed all manuscript changes included in the minireview article, analyzed the data, made critical reviews and wrote the final version of the manuscript; Dávalos-Cobián C, García-Correa J contributed with the data analysis, critical review of the results and writing of the final version of the manuscript.

**Conflict-of-interest:** The authors declare no conflict of interest.

**Data sharing:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Alejandro González-Ojeda, MD, PhD, FACS,** Research Unit in Clinical Epidemiology, Western Medical Center, Av. Belisario Domínguez 1000. Col. Independencia, Guadalajara, Jalisco 44340, México. avygail5@gmail.com

**Telephone**: +52-33-38485410

**Fax**: +52-33-384854213.

**Received:** December 3, 2014

**Peer-review started:** December 5, 2014

**First decision:** January 22, 2015

**Revised:** January 30, 2015

**Accepted:** April 28, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To determine whether or not the use of antioxidant supplementation aids in the prevention of post- endoscopic retrograde cholangiopancreatography pancreatitis.

**METHODS:** A systematic review of randomized controlled trials (RCTs) was made to evaluate the preventive effect of prophylactic antioxidant supplementation in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP). The inclusion criteria included: acute post-endoscopic retrograde cholangiopancreatography pancreatitis in adults; randomized clinical trials with the use of any antioxidant as an intervention compared with placebo, to reduce PEP. The outcome measure was the incidence and severity of PEP. Twelve RCTs involving 3110 patients since 1999were included. The antioxidants used were selenite, β-carotene, and pentoxifylline (each one in one trial), N-acetylcysteine (NAC) in three trials, and allopurinol in six trials. The group of patients treated with NAC received different doses; either oral or intravenous, and allopurinol-treated patients received five different oral doses in two different administration periods. The results are expressed with raw numbers, proportions, as well as mean and standard deviations. The incidence of pancreatitis between groups was analyzed with Pearson’s χ2 test or Fisher’s exact test (*F*). The main outcome is expressed as relative risks and 95%CI.

**RESULTS:** The incidence of pancreatitis in all antioxidant treatment groups was 8.6%, whereas it was 9.7% in the control group. The antioxidants used were selenite, β-carotene, and pentoxifylline (each one in one trial), NAC in three trials, and allopurinol in six trials. In allopurinol trials, three different dosifications were used; two trials reported a low dosage (of less than 400 mg), two trials reported a moderate dose (600 mg) and the remaining two employed higher doses (more than 900 mg). Supplementation was not associated with a significant reduction in the incidence of PEP [relative risk (RR) = 0.93; 95%CI: 0.82–1.06; *P =* 0.28]. In addition, the incidences of PEP in patients treated with allopurinol and those treated with other antioxidants were similar to that observed in patients who received the placebo (RR for trials with allopurinol, 0.92; 95%CI: 0.78–1.08; *P =* 0.31) and, with the use of other antioxidants, the incidence of PEP was 8.9%, whereas it was 9.7% in the control group (RR = 0.95; 95%CI: 0.77–1.18; *P =* 0.19).

**CONCLUSION:** Antioxidant supplementation shows no beneficial effect on the incidence of PEP. There is a lack of robust trials to support the use of antioxidants for prevention.

**Key words:** Antioxidant drugs; Endoscopic retrograde cholangiopancreatography; Pancreatitis; Prophylaxis

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Acute pancreatitis is considered one of the most serious complications after endoscopic retrograde cholangiopancreatography (ERCP). The mechanism of post-ERCP pancreatitis remains unclear but several studies show that free radicals play a role in its pathogenesis. Antioxidant drugs have been tested using different routes of administration and dosifications. The analysis of all randomized clinical trials published since 1999 did not revealed any significant reduction in the incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) when compared with placebo. There is currently a lack of robust trials to support the use of antioxidants for the prevention of PEP. Well-designed placebo-controlled randomized controlled trials are warranted to determine any beneficial effect.

Fuentes-Orozco C, Dávalos-Cobián C, García-Correa J, Ambriz-González G, Macías-Amezcua MD, García-Rentería J, Rendón-Félix J, Chávez-Tostado M, Cuesta-Márquez LA, Alvarez-Villaseñor AS, Cortés-Flores AO, González-Ojeda A. Antioxidant drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: What does evidence suggest? *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP)[1-4], with a reported incidence ranging from 1.8% to 7.2% in most prospective series[5-9]. However, the reported incidence may be up to 30%, depending on the criteria used to diagnose pancreatitis, the type and duration of patient follow-up, and the type of case mix[10]. More commonly, hyperamylasemia occurs in up to 30% of patients undergoing ERCP[11].

The generally accepted criteria for the diagnosis of post-ERCP pancreatitis (PEP) were proposed in 1991 during a consensus workshop. These criteria include the new onset of pancreatic-type abdominal pain associated with at least a three-fold increase in serum amylase or lipase occurring within 24 h after ERCP. The pain symptoms need to be sufficiently severe to require admission to a hospital or to extend the length of stay of patients who are already hospitalized[12]. Most of the episodes of acute pancreatitis are catalogued as mild. However, based on the presence of organ failure or local complications, acute severe pancreatitis occurs after 0.3% to 0.6% of ERCP procedures[10,13-15].

Numerous attempts have been made to identify a pharmacological agent that could be used to reduce the incidence and severity of PEP. An ideal agent should be highly effective in reducing PEP, safe for the patient, well tolerated, relatively affordable, and not require a prolonged administration time. Unfortunately, nearly all of the agents investigated have fallen short of these goals, but some agents have shown some promise[16,17]. An early step in the pathogenesis of acute pancreatitis is capillary endothelial injury manifested by an increase in capillary permeability[18,19]. Subsequent research has suggested that this capillary injury might be mediated by oxygen-derived free radicals[20-22]. The manifestations of pancreatitis in an experimental animal model can be ameliorated by blocking the action of oxygen-derived free radicals[23-25]. Xanthine oxidase catalyzes the conversion of hypoxanthine to xanthine, which generates an oxygen-derived free radical. This catalyst is commonly derived from a ubiquitous inactive precursor, xanthine dehydrogenase, which is present in the pancreas and in the intestinal mucosa. Xanthine dehydrogenase is converted to xanthine oxidase by the proteolytic cleavage of a peptide fragment. These findings have prompted attempts to prevent pancreatitis by treatment with free radical scavengers (*e.g*., superoxide dismutase, dimethyl sulfoxide, or catalase), protease inhibitors (*e.g*., gabexate), or xanthine oxidase inhibitors (*e.g*., allopurinol)[26-29].

The efficacy of oral allopurinol in reducing PEP has been investigated in an *in vivo* animal model[30]. Pretreatment was associated with a significant (six-fold) reduction in the incidence of pancreatitis; furthermore, when pancreatitis did occur, it was less severe. Other dog and rat models pretreated with allopurinol have demonstrated a significant reduction in the progression of histological pancreatic injury and in the severity of experimental pancreatitis[31-33].

Based on the aforementioned findings, the idea of antioxidant supplementation for the prevention of PEP seemed rational and reasonable. Therefore, we undertook this revision of randomized controlled trials (RCTs) to evaluate the effect of prophylactic antioxidant supplementation compared with placebo or no intervention on the incidence and severity of PEP.

**MATERIAL AND METHODS**

This systematic review included all articles published between January 1999 and December 2014, under the terms of: “antioxidants in pancreatitis in human beings”. Randomized controlled trials that included pancreatitis post ERCP were selected, making a comparison of the use of antioxidants against placebo.

The inclusion criteria included: acute pancreatitis post ERCP in adults; randomized clinical trials with an intervention of any antioxidant use compared with placebo, to reduce PEP. The outcome measure was the incidence and severity of PEP.

***Data extraction and outcome measure***

The authors extracted the manuscripts. All selected studies must have had the inclusion criteria, and the outcome results were captured in a database in Office® Excel® 2013 (Microsoft® Corp. Redmond, CA). Any disagreements were resolved by discussion and consensus to reach a common conclusion.

***Statistical analysis***

The results were expressed with raw numbers, proportions, as well as mean and standard deviations. The incidence of pancreatitis between groups was analyzed with χ2 test or Fisher Exact Test. The main outcome is expressed as relative risks and 95% confidence intervals (95%CIs).

**RESULTS**

***Study characteristics***

The main characteristics of the 12 RCTs included in this review are presented in Table 1, and the definition and severity of PEP used in each included trial are described in Table 2. These studies were published between 1999 and 2013. The sizes of the RCTs ranged from 40 to 701 (total, 3110) patients. All 12 studies included here reported post-ERCP pancreatitis events[34-45], eight reported mild and moderate PEP events[35-39,41,42,44], and six reported severe PEP events[35-37,39,41,42].

All patients were older than 18 years and were scheduled for ERCP. The selected trials used different types of antioxidants, including sodium selenite[34], allopurinol[35,38,39,42-44], N-acetylcysteine (NAC)[36,39,44], β-carotene[36], and pentoxifylline[41]. These antioxidants were administered orally or intravenously using different regimens and formulations. Two studies used an intravenous route to administer the antioxidant[21,25], whereas the remaining 10 studies applied the antioxidant orally during the perioperative period[23,24,26-32]. The dosage, timing, and frequency of these antioxidants were quite different.

***Incidence of PEP***

The outcome data of each included trial are described in Table 3. A total of 3110 patients were included in the 12 trials that compared antioxidants with placebo or no intervention for the prevention of PEP (1534 in the antioxidant group and 1576 in the control group). Altogether, 285 patients developed PEP (132 in the antioxidant group and 153 in the control group), with an incidence of 8.6% in the antioxidant group and 9.7% in the control group. Antioxidant supplementation was not associated with a significant reduction in the incidence of PEP [relative risk (RR) = 0.93; 95%CI: 0.82–1.06; *P =* 0.28]. Furthermore, when trials were divided according to the type of antioxidant, there was no significant decrease in PEP incidence (RR for trials with allopurinol, 0.92; 95%CI: 0.78–1.08; *P =* 0.31); the incidence in trials with other antioxidants was 8.9%, whereas it was 9.7% in the control group (RR = 0.95; 95%CI: 0.77–1.18; *P =* 0.19). When allopurinol studies were stratified according to the dosage of allopurinol, there was still no statistically significant preventive effect of allopurinol on mild, moderate, and severe PEP. Five doses of allopurinol were applied in these trials (300, 400, 600, 900, and 1200 mg), which were divided into three levels: low (300 and 400 mg), moderate (600 mg), and high (900 and 1200 mg).

Two RCTs[35,42] applied a low dosage of allopurinol. Budzynska *et al*[35] showed that allopurinol did not play a significant role in the incidence and severity of PEP. Similarly, Romagnuolo *et al*[42] concluded that the overall risk of PEP did not decrease after pretreatment with allopurinol. However, it might have potential benefits in the high-risk group, but it is potentially harmful (PEP rates: allopurinol, 5.4%; placebo, 1.5%) in the non-high-risk group. Nevertheless, in this study, the percentage of patients with pancreatic duct injection was significantly higher in the allopurinol group (allopurinol, 129; placebo, 102; *P =* 0.02), which might have resulted in a higher occurrence of PEP in the non-high-risk subgroup.

Two studies[43,44] investigated the preventive effect of a moderate dose of allopurinol. Martinez-Torres *et al*[43] indicated that pretreatment with allopurinol decreased the incidences of hyperamylasemia and PEP in patients undergoing high-risk procedures. However, Abbasinazari *et al*[44] drew the opposite conclusion after using the same dose of allopurinol, i.e., that there was no difference between allopurinol and placebo regarding prevention of the occurrence of PEP (*P =* 0.97). However, differences were found between the two RCTs regarding the drug administration time. In the research by Martinez-Torres *et al*[43], subjects were administered allopurinol at 15 h and 3 h before ERCP, whereas they received it at 3 h and just before ERCP in the study by Abbasinazari *et al*[44] It is necessary to assess whether administration time plays a part in the effect of allopurinol.

Two trials[38,39], both published in 2005, applied a high dose of allopurinol. Mosler *et al*[39] observed that the overall frequency of pancreatitis was 12.55% (allopurinol, 12.96%; placebo, 12.14%; *P =* 0.52). Moreover, there was no significant difference for mild (allopurinol, 7.9%; placebo, 6.9%), moderate (allopurinol, 4.5%; placebo, 4.6%), or severe (allopurinol, 0.6%; placebo, 0.6%) PEP separately.

By contrast, Katsinelos *et al*[38] held the view that the risk of PEP decreased at the highest dosage (1200 mg) of allopurinol. They observed four cases (3.2%) of mild PEP and 21 patients (17.7%) with PEP (RR = 0.29; 95%CI: 0.12–0.71; *P =* 0.001). In the control group, mild PEP was observed in 6.7%, moderate PEP was observed in 9.3%, and severe PEP was observed in 1.6% of individuals. The administration time of the two studies was not the same. Patients were administered allopurinol at 15 h and 3 h before ERCP in the study by Katsinelos *et al*[38], whereas they received it at 4 h and 1 h before ERCP in the study by Mosler *et al[*39]. Allopurinol is absorbed approximately to 90% of the total dose in the gastrointestinal tract. It has a rapid onset, and 70% of the drug administered can transform into a long-lasting active metabolite, oxypurinol, in the liver. Peak plasma levels of allopurinol and oxypurinol can be observed at 1.5 h and 4.5 h postadministration, respectively. The half-life of allopurinol is 1–2 h, and that of oxypurinol is about 15 h[46,47]. To assess whether the preventive effect of allopurinol is influenced by the time of administration, Cao *et al*[48] recently published a meta-analysis of six RCTs of allopurinol, and classified the administration time into two levels: long (15 and 3 h before ERCP) and short (4 and 1 h before ERCP; 3 h and just before ERCP; and 1 h before ERCP), to determine whether this variable influenced the incidence of PEP. Those authors could not demonstrate any significant difference between the long[35,38,43] and short[39,42,44] administration groups, in contrast to the results obtained by Katsinelos *et al*[38] and Martinez-Torres *et al*[43], who demonstrated a beneficial effect of allopurinol in the prevention of PEP after using a long administration time.

**DISCUSSION**

Some differences arose between the six RCTs of allopurinol. As specified previously, five different doses were used, and two different regimens of administration were employed; moreover, the risk factors were inconsistent in the RCTs mentioned above[35,38,39,42-44]. For example, male sex, days of hospitalization, and administration of allopurinol were considered risk factors by Katsinelos *et al*[38], whereas previous PEP, pancreatic injection, and pancreatic therapy were predictors of PEP in the study by Martinez-Torres *et al*[43], compared with the nonsignificant risk factors, such as sex, number of pancreatic injections, biliary sphincterotomy, and pancreatic stent placement, reported by Romagnuolo *et al*[42].

In terms of the problems mentioned above, and as recommended by Cao *et al*[49], we suggest performing a rigid determination of risk factors and classifying them into patient-related and procedure-related risk factors. Definite patient-related risk factors (suspected sphincter of Oddi dysfunction, female sex, and previous pancreatitis) and definite procedure-related risk factors (precut sphincterotomy and pancreatic injection) were listed in the European guidelines, which could act as a guide for future research.

In the remaining six trials, four different antioxidants were used[34,36,37,40,41,45]. The incidence of PEP in these six trials was 8.9% (49 cases among 548 patients receiving any of the four antioxidants), whereas it was 9.7% in the control group (*P =* 0.19; RR = 0.95; 95%CI: 0.77–1.18). Considering only the trials of NAC[37,40,45], the incidence of pancreatitis was 10.4% in the treatment group and 14.1% in the control group; however, the difference was not statistically significant (*P =* 0.22; RR = 0.83; 95%CI: 0.61–1.15).

Gu *et al*[50] published the most recent meta-analysis of antioxidants as prophylactic agents for PEP. Those authors evaluated 3010 patients and found no statistically significant difference in the incidence of PEP between the antioxidant group (8.5%) and the control group (9.1%; RR = 0.92; 95%CI: 0.65–1.32; *P =* 0.66). They concluded that there was a lack of strong evidence in support of the use of antioxidants to reduce the incidence of PEP or the severity of episodes. However, they recognized the limitations of the evaluated trials, as the dose, route, and time of administration, as well as the evaluation of the patients and procedure-related risk factors, were not uniform. For these reasons, they suggested performing more powerful RCTs to test specific doses, routes, and times of administration, as well as including extensive evaluation of the severity of pancreatitis episodes, risk factors, and subrogate outcome variables, such as hyperamylasemia and length of hospital stay.

Traditionally, stent placement in pancreatic ducts of small caliber (5 Fr) has been considered as the standard treatment to prevent PEP, and it is even recommended in the management guidelines for the prevention of pancreatitis in patients at high risk[51,52]. Recently, Akbar and colleagues published the results of a meta-analysis that included a total of 29 studies, comprising 22 of pancreatic stent placement and seven of the use of nonsteroidal anti-inflammatory drugs (NSAIDs), showing that both stenting and transrectal administration of NSAIDs are superior to placebo in the prevention of post-ERCP pancreatitis. The combination of transrectal NSAIDs and the use of stents together showed no greater effectiveness in the prevention of post- ERCP pancreatitis compared with each intervention alone[53].

Regarding pharmacological prophylaxis, it is possible that NSAIDs might be useful[48]. Since the publication by Elmunzer *et al*[15] in 2012, most medical centers have included the use of preoperative NSAIDs for the prevention of PEP. The rectal administration of 100 mg of diclofenac or indomethacin may be effective in preventing the incidence of PEP.

In conclusion, this review showed that the prophylactic use of antioxidants in different dosages and at different administration times had no preventive effect regarding the incidence of PEP. Further well-designed placebo-controlled RCTs are warranted to confirm the preventive effect of antioxidants in PEP.

**COMMENTS**

***Background***

Acute pancreatitis is considered one of the most serious complications after endoscopic retrograde cholangiopancreatography (ERCP). The mechanism of post-ERCP pancreatitis remains unclear but several studies show that free radicals play a role in its pathogenesis. Antioxidant drugs have been tested using different routes of administration and dosifications. The analysis of all randomized clinical trials published since 1999 did not revealed any significant reduction in the incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) when compared with placebo.

***Research frontiers***

There is currently a lack of robust trials to support the use of antioxidants for the prevention of PEP. Well-designed placebo-controlled randomized controlled trials are warranted to determine any beneficial effect. Numerous attempts have been made to identify a pharmacological agent that could be used to reduce the incidence and severity of PEP.

***Applications***

Antioxidant supplementation shows no beneficial effect on the incidence of PEP. There is a lack of robust trials to support the use of antioxidants for prevention.

***Peer-review***

The manuscript by Fuentes-Orozco and colleagues is a review of antioxidant therapy to prevent post-ERCP. The authors appropriately focus on the randomized clinical trials (those published between 1999 and 2013). The authors present a well written and thorough review the theoretical basis for antioxidants and the available clinical work on this topic.

**REFERENCES**

|  |
| --- |
| 1 **Freeman ML**, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, Overby CS, Aas J, Ryan ME, Bochna GS, Shaw MJ, Snady HW, Erickson RV, Moore JP, Roel JP. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. *Gastrointest Endosc* 2001; **54**: 425-434 [PMID: 11577302 DOI: 10.1067/mge.2001.117550]  2 **Freeman ML**, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, Ryan ME, Shaw MJ, Lande JD, Pheley AM. Complications of endoscopic biliary sphincterotomy. *N Engl J Med* 1996; **335**: 909-918 [PMID: 8782497 DOI: 10.1056/NEJM199609263351301]  3 **Andriulli A**, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, Leandro G, Leo P, De Maio G, Perri F. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. *Gastrointest Endosc* 2002; **56**: 488-495 [PMID: 12297762 DOI: 10.1067/mge.2002.128130]  4 **Christoforidis E**, Goulimaris I, Kanellos I, Tsalis K, Demetriades C, Betsis D. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. *Endoscopy* 2002; **34**: 286-292 [PMID: 11932783 DOI: 10.1055/s-2002-23630]  5 **Masci E**, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, Minoli G, Crosta C, Comin U, Fertitta A, Prada A, Passoni GR, Testoni PA. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. *Am J Gastroenterol* 2001; **96**: 417-423 [PMID: 11232684 DOI: 10.1111/j.1572-0241.2001.03594.x]  6 **Vandervoort J**, Soetikno RM, Tham TC, Wong RC, Ferrari AP, Montes H, Roston AD, Slivka A, Lichtenstein DR, Ruymann FW, Van Dam J, Hughes M, Carr-Locke DL. Risk factors for complications after performance of ERCP. *Gastrointest Endosc* 2002; **56**: 652-656 [PMID: 12397271 DOI: 10.1016/S0016-5107(02)70112-0]  7 **García-Cano Lizcano J**, González Martín JA, Morillas Ariño J, Pérez Sola A. Complications of endoscopic retrograde cholangiopancreatography. A study in a small ERCP unit. *Rev Esp Enferm Dig* 2004; **96**: 163-173 [PMID: 15053731 DOI: 10.4321/S1130-01082004000300002]  8 **Cheng CL**, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, Frakes JT, Fogel EL, Silverman WB, Dua KS, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J, Lazzell-Pannell L, Rashdan A, Temkit M, Lehman GA. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. *Am J Gastroenterol* 2006; **101**: 139-147 [PMID: 16405547 DOI: 10.1111/j.1572-0241.2006.00380.x]  9 **Williams EJ**, Taylor S, Fairclough P, Hamlyn A, Logan RF, Martin D, Riley SA, Veitch P, Wilkinson ML, Williamson PR, Lombard M. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. *Endoscopy* 2007; **39**: 793-801 [PMID: 17703388 DOI: 10.1055/s-2007-966723]  10 **Freeman ML**, Guda NM. Prevention of PEP: a comprehensive review. *Gastrointest Endosc* 2004; **59**: 845-864 [PMID: 15173799 DOI: 10.1016/S0016-5107(04)00353-0]  11 **LaFerla G**, Gordon S, Archibald M, Murray WR. Hyperamylasaemia and acute pancreatitis following endoscopic retrograde cholangiopancreatography. *Pancreas* 1986; **1**: 160-163 [PMID: 2437564 DOI: 10.1097/00006676-198603000-00009]  12 **Cotton PB**, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N. Endoscopic sphincterotomy complications and their management: an attempt at consensus. *Gastrointest Endosc* 1991; **37**: 383-393 [PMID: 2070995 DOI: 10.1016/S0016-5107(91)70740-2]  13 **Vaira D**, D'Anna L, Ainley C, Dowsett J, Williams S, Baillie J, Cairns S, Croker J, Salmon P, Cotton P. Endoscopic sphincterotomy in 1000 consecutive patients. *Lancet* 1989; **2**: 431-434 [PMID: 2569609 DOI: 10.1016/S0140-6736(89)90602-8]  14 **Barthet M**, Lesavre N, Desjeux A, Gasmi M, Berthezene P, Berdah S, Viviand X, Grimaud JC. Complications of endoscopic sphincterotomy: results from a single tertiary referral center. *Endoscopy* 2002; **34**: 991-997 [PMID: 12471544 DOI: 10.1055/s-2002-35834]  15 **Elmunzer BJ**, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA, Romagnuolo J, Elta GH, Sherman S, Waljee AK, Repaka A, Atkinson MR, Cote GA, Kwon RS, McHenry L, Piraka CR, Wamsteker EJ, Watkins JL, Korsnes SJ, Schmidt SE, Turner SM, Nicholson S, Fogel EL. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. *N Engl J Med* 2012; **366**: 1414-1422 [PMID: 22494121 DOI: 10.1056/NEJMoa1111103]  16 **Rodríguez Muñoz S**. Towards safer ERCP: selection, experience and prophylaxis. *Rev Esp Enferm Dig* 2004; **96**: 155-162 [PMID: 15053730 DOI: ]  17 **Cooper ST**, Slivka A. Incidence, risk factors, and prevention of post-ERCP pancreatitis. *Gastroenterol Clin North Am* 2007; **36**: 259-76, vii-viii [PMID: 17533078 DOI: 10.1016/j.gtc.2007.03.006]  18 **Broe PJ**, Cameron JL. Experimental gallstone pancreatitis. Pathogenesis and response to different treatment modalities. *Ann Surg* 1982; **195**: 566-573 [PMID: 6176193 DOI: 10.1097/00000658-198205000-00005]  19 **Sanfey H**, Cameron JL. Increased capillary permeability: an early lesion in acute pancreatitis. *Surgery* 1984; **96**: 485-491 [PMID: 6206583]  20 **Sanfey H**, Bulkley GB, Cameron JL. The role of oxygen-derived free radicals in the pathogenesis of acute pancreatitis. *Ann Surg* 1984; **200**: 405-413 [PMID: 6207783 DOI: 10.1097/00000658-198410000-00003]  21 **Schoenberg MH**, Büchler M, Beger HG. Oxygen radicals in experimental acute pancreatitis. *Hepatogastroenterology* 1994; **41**: 313-319 [PMID: 7959564]  22 **Seo JY**, Kim H, Seo JT, Kim KH. Oxidative stress induced cytokine production in isolated rat pancreatic acinar cells: effects of small-molecule antioxidants. *Pharmacology* 2002; **64**: 63-70 [PMID: 11803245 DOI: 10.1159/000056152]  23 **Demols A**, Van Laethem JL, Quertinmont E, Legros F, Louis H, Le Moine O, Devière J. N-acetylcysteine decreases severity of acute pancreatitis in mice. *Pancreas* 2000; **20**: 161-169 [PMID: 10707932 DOI: 10.1097/00006676-200003000-00009]  24 **Wisner JR**, Renner IG. Allopurinol attenuates caerulein induced acute pancreatitis in the rat. *Gut* 1988; **29**: 926-929 [PMID: 2456257 DOI: 10.1136/gut.29.7.926]  25 **Nonaka A**, Manabe T, Tobe T. Effect of a new synthetic ascorbic acid derivative as a free radical scavenger on the development of acute pancreatitis in mice. *Gut* 1991; **32**: 528-532 [PMID: 1710198 DOI: 10.1136/gut.32.5.528]  26 **Cavallini G**, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. *N Engl J Med* 1996; **335**: 919-923 [PMID: 8786777 DOI: 10.1056/NEJM199609263351302]  27 **Masci E**, Cavallini G, Mariani A, Frulloni L, Testoni PA, Curioni S, Tittobello A, Uomo G, Costamagna G, Zambelli S, Macarri G, Innocenti P, Dragonetti C. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. *Am J Gastroenterol* 2003; **98**: 2182-2186 [PMID: 14572565 DOI: 10.1111/j.1572-0241.2003.07698.x]  28 **Sanfey H**, Bulkley GB, Cameron JL. The pathogenesis of acute pancreatitis. The source and role of oxygen-derived free radicals in three different experimental models. *Ann Surg* 1985; **201**: 633-639 [PMID: 2581519 DOI: 10.1097/00000658-198505000-00013]  29 **Nordback IH**, Cameron JL. The mechanism of conversion of xanthine dehydrogenase to xanthine oxidase in acute pancreatitis in the canine isolated pancreas preparation. *Surgery* 1993; **113**: 90-97 [PMID: 8417495]  30 **Marks JM**, Dunkin BJ, Shillingstad BL, Youngelman DF, Schweitzer MA, Lash RH, Singh J, Ponsky L, Ponsky JL. Pretreatment with allopurinol diminishes pancreatography-induced pancreatitis in a canine model.*Gastrointest Endosc* 1998; **48**: 180-183 [PMID: 9717784 DOI: 9717784 10.1016/S0016-5107(98)70160-9]  31 **Isik AT**, Mas MR, Yamanel L, Aydin S, Comert B, Akay C, Erdem G, Mas N. The role of allopurinol in experimental acute necrotizing pancreatitis. *Indian J Med Res* 2006; **124**: 709-714 [PMID: 17287560]  32 **Shabanov VV**, Milyakova MN, Minyailov NA. Antiradical effect of allopurinol at early stages of experimental acute pancreatitis. *Bull Exp Biol Med* 2006; **142**: 29-31 [PMID: 17369895 DOI: 10.1007/s10517-006-0283-0]  33 **Comert B**, Isik AT, Aydin S, Bozoglu E, Unal B, Deveci S, Mas N, Cinar E, Mas MR. Combination of allopurinol and hyperbaric oxygen therapy: a new treatment in experimental acute necrotizing pancreatitis? *World J Gastroenterol* 2007; **13**: 6203-6207 [PMID: 18069760 DOI: 10.3748/wjg.13.6203]  34 **Wollschläger S**, Pätzold K, Bulang T, Meissner D, Porst H. Effect of preventive selenium administration on development of ERCP-induced acute pancreatitis. *Med Klin (Munich)* 1999; **94 Suppl 3**: 81-83 [PMID: 10554538 DOI: 10.1007/BF03042200]  35 **Budzyńska A**, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. *Endoscopy* 2001; **33**: 766-772 [PMID: 11558030 DOI: 10.1055/s-2001-16520]  36 **Lavy A**, Karban A, Suissa A, Yassin K, Hermesh I, Ben-Amotz A. Natural beta-carotene for the prevention of post-ERCP pancreatitis. *Pancreas* 2004; **29**: e45-e50 [PMID: 15257114 DOI: 10.1097/00006676-200408000-00018]  37 **Katsinelos P**, Kountouras J, Paroutoglou G, Beltsis A, Mimidis K, Zavos C. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. *Gastrointest Endosc* 2005; **62**: 105-111 [PMID: 15990827 DOI: 10.1016/S0016-5107(05)01574-9]  38 **Katsinelos P**, Kountouras J, Chatzis J, Christodoulou K, Paroutoglou G, Mimidis K, Beltsis A, Zavos C. High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial. *Gastrointest Endosc* 2005; **61**: 407-415 [PMID: 15758912 DOI: 10.1016/S0016-5107(04)02647-1]  39 **Mosler P**, Sherman S, Marks J, Watkins JL, Geenen JE, Jamidar P, Fogel EL, Lazzell-Pannell L, Temkit M, Tarnasky P, Block KP, Frakes JT, Aziz AA, Malik P, Nickl N, Slivka A, Goff J, Lehman GA. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. *Gastrointest Endosc* 2005; **62**: 245-250 [PMID: 16046988 DOI: 10.1016/S0016-5107(05)01572-5]  40 **Milewski J**, Rydzewska G, Degowska M, Kierzkiewicz M, Rydzewski A. N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. *World J Gastroenterol* 2006; **12**: 3751-3755 [PMID: 16773694]  41 **Kapetanos D**, Kokozidis G, Christodoulou D, Mistakidis K, Sigounas D, Dimakopoulos K, Kitis G, Tsianos EV. A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis. *Gastrointest Endosc* 2007; **66**: 513-518 [PMID: 17725940 DOI: 10.1016/j.gie.2007.03.1045]  42 **Romagnuolo J**, Hilsden R, Sandha GS, Cole M, Bass S, May G, Love J, Bain VG, McKaigney J, Fedorak RN. Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial. *Clin Gastroenterol Hepatol* 2008; **6**: 465-71; quiz 371 [PMID: 18304883 DOI: 10.1016/j.cgh.2008.02.017]  43 **Martinez-Torres H**, Rodriguez-Lomeli X, Davalos-Cobian C, Garcia-Correa J, Maldonado-Martinez JM, Medrano-Muñoz F, Fuentes-Orozco C, Gonzalez-Ojeda A. Oral allopurinol to prevent hyperamylasemia and acute pancreatitis after endoscopic retrograde cholangiopancreatography. *World J Gastroenterol* 2009; **15**: 1600-1606 [PMID: 19340902 DOI: 10.3748/wjg.15.1600]  44 **Abbasinazari M**, Mohammad Alizadeh AH, Moshiri K, Pourhoseingholi MA, Zali MR. Does allopurinol prevent post endoscopic retrograde cholangio- pancreatography pancreatitis? A randomized double blind trial. *Acta Med Iran* 2011; **49**: 579-583 [PMID: 22052140]  45 **Alavi Nejad P**, Hajiani E, Hashemi J, Masjedizadeh AR, Shayesteh AA, Sebghatollahi V. Evaluation of N-acetyl Cysteine for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective Double Blind Randomized Pilot Study. *Middle East J Dig Dis* 2013; **5**: 17-21 [PMID: 24829665]  46 **Kountouras J**, Chatzopoulos D, Zavos C. Reactive oxygen metabolites and upper gastrointestinal diseases. *Hepatogastroenterology* 2001; **48**: 743-751 [PMID: 11462918]  47 **Pacher P**, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. *Pharmacol Rev* 2006; **58**: 87-114 [PMID: 16507884 DOI: 10.1124/pr.58.1.6]  48 **Cao WL**, Yan WS, Xiang XH, Chen K, Xia SH. Prevention effect of allopurinol on post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of prospective randomized controlled trials. *PLoS One* 2014; **9**: e107350 [PMID: 25202907 DOI: 10.1371/journal.pone.0107350]  49 **Dumonceau JM**, Andriulli A, Elmunzer BJ, Mariani A, Meister T, Deviere J, Marek T, Baron TH, Hassan C, Testoni PA, Kapral C. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014. *Endoscopy* 2014; **46**: 799-815 [PMID: 25148137 DOI: 10.1055/s-0034-1377875]  50 **Gu WJ**, Wei CY, Yin RX. Antioxidant supplementation for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. *Nutr J* 2013; **12**: 23 [PMID: 23398675 DOI: 10.1186/1475-2891-12-23]  51 **Tenner S**, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology guideline: management of acute pancreatitis. *Am J Gastroenterol* 2013; **108**: 1400-115; 1416 [PMID: 23896955 DOI: 10.1038/ajg.2013.218]  52 **Mazaki T**, Mado K, Masuda H, Shiono M. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. *J Gastroenterol* 2014; **49**: 343-355 [PMID: 23612857 DOI: 10.1007/s00535-013-0806-1]  53 **Akbar A**, Abu Dayyeh BK, Baron TH, Wang Z, Altayar O, Murad MH. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. *Clin Gastroenterol Hepatol* 2013; **11**: 778-783 [PMID: 23376320 DOI: 10.1016/j.cgh.2012.12.043] |

**P-Reviewer:** Schneider E, Sferra TJ **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Table 1 Main characteristics of the randomized controlled trials included in this study**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **No. of patients (antioxidant/ placebo)** | **Patient characteristics** | **Antioxidant supplement** | | **Intervention**  **Antioxidant group Control group** | | **Study design** |
| **Wollschläger*et al*[33], 1999** | 40  (20/20) | Patients undergoing ERCP | | Selenite | Selenite, IV, 1 mg bolus/2 × 1 mg infusion, l d before ERCP | Control, no prophylaxis | Randomized, controlled |
| **Budzynska *et al*[34], 2001** | 200  (99/101) | Patients undergoing elective ERCP | | Allopurinol | Allopurinol, orally, 200 mg, 15 h and 3 h before ERCP | Placebo, orally, 200 mg, 15 and 3 h before ERCP | Randomized, placebo-controlled |
| **Lavy *et al*[35], 2004** | 321  (141/180) | Patients undergoing ERCP | | β-carotene | β-carotene, orally, 2 g, 12 h before ERCP | Placebo, orally, 2 g, 12 h before ERCP | Randomized, double-blind, placebo-controlled |
| **Katsinelos *et al*[36], 2005** | 249  (124/125) | Patients undergoing diagnostic or therapeutic ERCP | | NAC | NAC, IV, 70 mg/kg 2 h before, and 35 mg/kg at 4 h intervals for 24 h after ERCP | Placebo), IV, 70 mg/kg 2 h before, and 35 mg/kg at 4 h intervals for 24 h after ERCP | Randomized, double-blind, placebo-controlled |
| **Katsinelos *et al*[37], 2005** | 243  (125/118) | Patients undergoing diagnostic or therapeutic ERCP | | Allopurinol | Allopurinol, orally, 600 mg, 15 and 3 h before ERCP | Placebo, orally, 600 mg, 15 and 3 h before ERCP | Randomized, double-blind, placebo-controlled |
| **Mosler *et al*[38], 2005** | 701  (355/346) | Patients undergoing diagnostic or therapeutic ERCP | | Allopurinol | Allopurinol, orally, 4 h (600 mg) and 1 h (300 mg) before ERCP | Placebo, orally, 4 h (600 mg) and 1 h (300 mg) before ERCP | Randomized, double-blind, placebo-controlled |
| **Milewski *et al*[39], 2006** | 106  (55/51) | Patients undergoing ERCP | | NAC | NAC, two doses of 600 mg orally 24 h and 12 h before ERCP, and 600 mg IV for 2 d after ERCP | Placebo IV, twice a day for 2 d after ERCP | Randomized, placebo-controlled |
| **Kapetanos *et al*[40], 2007** | 320  (158/162) | Patients undergoing ERCP | | Pentoxifylline | Pentoxifylline, orally, 400 mg, 1 d before ERCP (2 and 10 pm) until the night after ERCP (6 am, 2 and 10 pm) | No intervention | Randomized, controlled |
| **Romagnuolo *et al*[41], 2008** | 586  (293/293) | Patients undergoing ERCP | | Allopurinol | Allopurinol, orally, 300 mg, 1 h before ERCP | Placebo, orally, 300 mg, 1 h before ERCP | Randomized, double-blind, placebo-controlled |
| **Martinez-Torres *et al*[42], 2009** | 170  (85/85) | Patients undergoing ERCP | | Allopurinol | Allopurinol, orally, 300 mg, 15 and 3 h before ERCP | Placebo, orally, 300 mg, 15 and 3 h before ERCP | Randomized, placebo-controlled |
| **Abbasinazari *et al*[43], 2011** | 74  (29/45) | Patients undergoing ERCP | | Allopurinol | Allopurinol, orally, 300 mg, 15 and 3 h before ERCP | Placebo, orally, 300 mg, 15 and 3 h before ERCP | Randomized, double-blind, placebo-controlled |
| **Alavi *et al*[44], 2013** | 100  (50/50) | Patients undergoing ERCP | | NAC | NAC, 1200 mg with 150 mL water orally 2 h before ERCP | Placebo,, orally 2 h before ERCP | Randomized, double-blind, placebo-controlled |

ERCP: Endoscopic retrograde cholangiopancreatography; IV: Intravenously; NAC: N-acetylcysteine.

**Table 2 Definition and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis**

|  |  |  |
| --- | --- | --- |
| Study | Definition of post-ERCP pancreatitis | Severity of post-ERCP pancreatitis |
| Wollschläger*et al*[33], 1999 | Abdominal pain attributed to pancreatitis, in association with a serum lipase or amylase level ≥2 times the upper limit of normal. | NA |
| Budzynska *et al*[34], 2001 | Abdominal pain attributed to pancreatitis, together with a need for an unplanned hospitalization or an extension of a planned hospitalization by at least 2 d, and a serum amylase level ≥3 times the upper limit of normal at 24 h after ERCP. | **Mild**: symptoms lasting up to 3 d and pancreas normal on the CT scan. **Moderate**: requiring specific therapeutic measures for 4–10 d, Balthazar’s grade B/C on CT. **Severe**: local or systemic complications for more than 10 d, Balthazar’s grade D/F on CT, or death. |
| Lavy *et al*[35], 2004 | Abdominal pain attributed to pancreatitis, in association with an amylase level ≥3 times the upper limit of normal. | **Mild**: requiring 2–3 d of hospitalization. **Moderate**: requiring 4–10 d of hospitalization. **Severe**: requiring 10 d of hospitalization or requiring surgical intervention or leading to death. |
| Katsinelos *et al*[36], 2005 | Abdominal pain attributed to pancreatitis, together with a need for an unplanned hospitalization or an extension of a planned hospitalization by at least 2 d, and a serum amylase level ≥3 times the upper limit of normal at 24 h after ERCP. | **Mild**: symptoms persisting for 3 d and a normal appearance of the pancreas by US and/or CT. **Moderate**: requirement for specific therapeutic measures for 4–10 d (Balthazar’s grade B/C on CT). **Severe**: local or systemic complications for more than 10 d after ERCP (Balthazar’s grade D/F) or death. |
| Katsinelos *et al*[37], 2005 | Abdominal pain attributed to pancreatitis, together with a need for an unplanned hospitalization or an extension of a planned hospitalization by at least 2 d, and a serum amylase level ≥3 times above the upper limit of normal at 24 h after ERCP. | **Mild**: symptoms persisting for 3 d and a normal appearance of the pancreas by US and/or CT. **Moderate**: requirement for specific therapeutic measures for 4–10 d (Balthazar’s grade B/C on CT). **Severe**: local or systemic complications for more than 10 d after ERCP (Balthazar’s grade D/F) or death. |
| Mosler *et al*[38], 2005 | New-onset or increased abdominal pain lasting for more than 24 h, causing the unplanned admission of an outpatient for more than one night or prolonging a planned admission of an inpatient, and associated with a serum amylase level ≥3 times the normal level, at approximately 18 h (the next morning) after ERCP. | **Mild**: hospitalization lasting 2–3 d. **Moderate**: hospitalization lasting 4–10 d. **Severe**: hospitalization prolonged for more than 10 d or any of the following: hemorrhagic pancreatitis, pancreatic necrosis, pancreatic pseudocyst, or the need for percutaneous drainage or surgery. |
| Milewski *et al*[39], 2006 | Clinical features consistent with acute pancreatitis beginning after ERCP and lasting for at least 24 h, associated with a serum amylase level >5 times the normal level. | NA |
| Kapetanos *et al*[40], 2007 | Abdominal pain attributed to pancreatitis, together with a need for an unplanned hospitalization or an extension of a planned hospitalization by at least 2 d, and a serum amylase level ≥3 times the upper limit of normal at 24 h after ERCP. | **Mild**: clinical pancreatitis and serum amylase at least three times higher than normal at more than 24 h after ERCP, requiring admission or prolongation of planned admission for 2–3 d. **Moderate**: required hospitalization for 4–10 d. **Severe**: required hospitalization for more than 10 d, an intervention (percutaneous drainage or surgery), or diagnosis of a pseudocyst. |
| Romagnuolo *et al*[41], 2008 | Abdominal pain attributed to pancreatitis requiring medical attention, in association with a serum lipase or amylase level >2 times the upper limit of normal. | NA |
| Martinez-Torres *et al*[42], 2009 | Serum amylase level above 600 IU/L or ≥3 times the normal value, and sharp pain irradiating to the back and nausea or vomiting. | **Mild**: two or fewer signs from Ranson’s criteria. **Moderate**: three to six signs. **Severe**: more than six signs. The criteria were as follows. At admission: age, > 55 yr; WBC count, >16,000/μL; serum glucose level, > 11.1 mmol/L; SLDH/ALT, > 350 IU/L; AST level, > 250 IU/L. During initial 48 h: hematocrits, decrease of more than 0.10; BUN level, increase of more than 5 mg/dL; calcium, < 2 mmol/L; PaO2, <60 mmHg; base deficit, > 4 mmol/L; fluid sequestration, > 6 L. |
| Abbasinazari *et al*[43], 2011 | NA | **Mild**: amylase concentration at least three times the upper limit of normal at more than 24 h after ERCP, requiring admission for 2–3 d. Moderate: admission for 4–10 d. **Severe**: admission for more than 10 d. |
| Alavi *et al*[44], 2013 | Serum amylase level > 275 U/mL or serum lipase level >1000 U/mL with the presence of abdominal pain. | The severity of pancreatitis based on the number of hospitalized days following ERCP. **Mild**: < 4 d. **Moderate**: 4–10 d. **Severe**: > 10 d. |

CT: Computed tomography; US: Ultrasound; ERCP: Endoscopic retrograde cholangiopancreatography; NA: Not available; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; SLDH/ALT: Serum lactate dehydrogenate to alanine aminotransferase ratio; WBC: White blood cell.

**Table 3 Outcome data of the randomized controlled trials included in this study**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Antioxidant group** | | | | | **Control group** | | | | |
| No. of patients (*n*) | No. of PEP cases (*n*) | PEP stratified according to severity | | | No. of patients (*n*) | No. of PEP cases (*n*) | PEP stratified according to severity | | |
| Mild | Moderate | Severe | Mild | Moderate | Severe |
| **Wollschläger*et al*[33], 1999** | 20 | 2 | NA | NA | NA | 20 | 3 | NA | NA | NA |
| **Budzynska *et al*[34], 2001** | 99 | 12 | 9 | 2 | 1 | 101 | 8 | 5 | 3 | 0 |
| **Lavy *et al*[35], 2004** | 141 | 14 | 10 | 4 | 0 | 180 | 17 | 9 | 4 | 4 |
| **Katsinelos *et al*[36], 2005** | 124 | 15 | 8 | 7 | 0 | 125 | 12 | 7 | 5 | 0 |
| **Katsinelos *et al*[37], 2005** | 125 | 4 | 4 | 0 | 0 | 118 | 21 | 8 | 11 | 2 |
| **Mosler *et al*[38], 2005** | 355 | 46 | 28 | 16 | 2 | 346 | 42 | 24 | 16 | 2 |
| **Milewski *et al*[39], 2006** | 55 | 4 | NA | NA | NA | 51 | 6 | NA | NA | NA |
| **Kapetanos *et al*[40], 2007** | 158 | 9 | 6 | 1 | 2 | 162 | 5 | 4 | 0 | 1 |
| **Romagnuolo *et al*[41], 2008** | 293 | 16 | 8 | 6 | 2 | 293 | 12 | 4 | 6 | 2 |
| **Martinez-Torres *et al*[42], 2009** | 85 | 2 | 2 | 0 | 0 | 85 | 8 | 8 | 0 | 0 |
| **Abbasinazari *et al*[43], 2011** | 29 | 3 | 2 | 1 | 0 | 45 | 5 | 3 | 2 | 0 |
| **Alavi *et al*[44], 2013** | 50 | 5 | NA | NA | NA | 50 | 14 | NA | NA | NA |
| **Total** | **1534** | **132** |  |  |  | **1576** | **153** |  |  |  |

ERCP: Endoscopic retrograde cholangiopancreatography; PEP: Post-ERCP pancreatitis; NA: Not available.